Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
05 août 2021 07h32 HE
|
Salarius Pharmaceuticals, Inc.
Clinical Trial in Hematologic Cancers Initiated and Initial Patients Enrolled in Expanded Sarcoma Clinical Trial; Multiple Potential Data Readouts Expected in 2021 and 2022 Preliminary Efficacy...
Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results
29 juil. 2021 07h33 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit
14 juil. 2021 08h05 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 14, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
13 juil. 2021 07h33 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference
09 juil. 2021 07h33 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 09, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
17 juin 2021 08h03 HE
|
Salarius Pharmaceuticals, Inc.
Online Event Scheduled for Monday, June 21, 2021, at 2:00 p.m., ET Event to Spotlight Seclidemstat and Feature Experts in the Fields of Epigenetics, Sarcomas, and Hematological Cancers HOUSTON, June...
Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers
15 juin 2021 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
10 juin 2021 13h30 HE
|
Salarius Pharmaceuticals, Inc.
Online Event Scheduled for Monday, June 21, 2021 at 2:00 p.m., ET Event to Spotlight Seclidemstat and Feature Experts in the Fields of Epigenetics, Sarcomas, and Hematological Cancers HOUSTON, June ...
Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’s Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
07 juin 2021 07h35 HE
|
Salarius Pharmaceuticals, Inc.
Presentations highlight full data from dose-escalation stage of Phase 1/2 clinical trial in Ewing sarcoma and interim data from Advanced Solid Tumor (AST) trial Initial drug activity observed in both...
Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
19 mai 2021 17h01 HE
|
Salarius Pharmaceuticals, Inc.
Preliminary drug activity observed in both relapsed/refractory Ewing sarcoma and Advanced Solid Tumor (AST) trials Presentations include full data from dose-escalation stage of Phase 1/2...